





% INCREASE OF ⁴⁵ Ca






















9/36

Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.

Title: Methods of Treating Multiple Myeloma and Myeloma-Induced Bone Resorption Using Integrin Antagonists










FIG.12

13 / 36





FIG. 13

Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.


Title: Methods of Treating Multiple Myeloma and Myeloma-Induced Bone Resorption Using Integrin Antagonists

14/36




Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.
Title: Methods of Treating Multiple Myeloma and
Myeloma-Induced Bone Resorption Using Integrin
Antagonists

15/36




-1G. 1E


16/36



⁵16. 16




18/36



19/36


1 (200 MICROGRAM) PS/2 TREATMENT / 1DAY N=3 / GROUP




2 (200 MICROGRAM) PS/2 TREATMENTS / 2DAYS N=3 / GROUP




6 (200 MICROGRAM) PS/2 TREATMENTS / 6DAYS N=5 / GROUP






Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.
Title: Methods of Treating Multiple Myeloma and
Myeloma-Induced Bone Resorption Using Integrin
Antagonists





Docket No. A061CIP2
Application No.: Not Yet Assigned inventor: MUNDY et al.
Title: Methods of Treating Multiple Myeloma and Myeloma-Induced Bone Resorption Using Integrin Antagonists


22/36



PERCENTAGE IGG2b CYTOPLASMIC POSITIVE CELLS

Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.
Title: Methods of Treating Multiple Myeloma and
Myeloma-Induced Bone Resorption Using Integrin
Antagonists


23 / 36





At down four things from more in many with the last through the control of the last through the last through

The street of th



5TGM1 CELLS (1E6) WERE INJECTED (I.V.) ON DAY O EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20 AND DAY 27

GROUPS N=3/GROUP


DISEASE FREE CONTROL UNTREATED MYELOMA CONTROL MELPHALAN TREATMENT--100 MICROGRAMS/INJECTION


PS/2 TREATMENT--100 MICROGRAMS/INJECTION MELPHALAN AND PS/2


MELPHALAN AND rIGG2b ISOTYPE CONTROL


Docket No. A061CIP2
Application No.: Not Yet Assigned
Inventor: MUNDY et al.
Title: Methods of Treating Multiple Myeloma and
Myeloma-Induced Bone Resorption Using Integrin
Antagonists












F/G. 28

	DAY 20	DAY27
	PS/2 PLASMA LEVELS	PS/2 PLASMA LEVELS
8-PS/2	NONE DETECETED	NONE DECTECTED
9-P2/2	NONE DETECTED	NONE DETECTED
10-PS/2	NONE DETECTED	NONE DETECTED
11-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED
12-MELPHALAN+PS/2	3.7 µg/ml	NONE DETECTED
13-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED

29 / 36

FIG. 29





5TGM1 CELLS (1E6) INJECTED (I.V.) ON DAY 0 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20

GROUPS N=2/GROUP

DISEASE FREE CONTROL UNTREATED MYELOMA CONTROL PS/2--100 MICROGRAMS/INJECTION Sm.Mol. 8809--3mg/kg, 0.3 mg/kg Sm.Mol. 9257 CONTROL--3 mg/kg








32 / 36

FIG.32

7 **PS/2** 20 6 **PS/2** 8 PS/2 Sm. Mol. 1 PS/2 Sm. Mol. 16 PS/2 Sm. Mol. 5 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 21 4 SMALL MOLECULE WAS GIVEN ON DAYS 15,16 AND 17 ,18,19 AND 20 5TGM1 CELLS (1E6) INJECTED (I.V.) ON DAY 0 PS/2 WAS GIVEN ON DAYS 15,16,17 DAY


GROUPS N=2/GROUP


DISEASE FREE CONTROL UNTREATED MYELOMA CONTROL PS/2--100 MICROGRAMS/INJECTION 8809--3mg/kg, 0.3 mg/kg OR 0.03 mg/kg 9257 CONTROL--3 mg/kg




34 / 36









The state of the s

